
Quarterly report 2025-Q4
added 03-09-2026
Anixa Biosciences Cash Flow 2011-2026 | ANIX
Annual Cash Flow Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-7.17 M | -7.34 M | -6.21 M | -6.49 M | -4.94 M | -6.18 M | -4.74 M | -4.27 M | -3.8 M | -3.38 M | 1.36 M | -2.38 M | -3.19 M | -3.14 M | -716 K |
Depreciation & Amortization |
- | - | - | - | - | 38.3 K | 47.6 K | 18.4 K | 43.2 K | 33.3 K | 12.5 K | 314 K | - | 7.23 K | 7.98 K |
Accounts Payables |
165 K | 525 K | 206 K | 265 K | 136 K | 232 K | 586 K | 582 K | 480 K | 373 K | 375 K | 540 K | 527 K | 305 K | 375 K |
Accounts Receivables |
- | 173 K | 270 K | 46 K | - | - | 66.5 K | - | - | - | - | 400 K | 175 K | - | - |
All numbers in USD currency
Quarterly Cash Flow Anixa Biosciences
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-2.61 M | - | - | - | -2.9 M | - | - | - | -2.31 M | - | - | - | -1.99 M | -4.9 M | - | - | -1.17 M | -3.89 M | -2.41 M | - | -1.91 M | -4.76 M | -3.47 M | - | -1.33 M | -3.4 M | -2.76 M | - | -1.34 M | -3.25 M | -2.08 M | - | -730 K | -3.06 M | -1.81 M | - | -532 K | -2.7 M | -1.88 M | - | 4.65 M | 2.17 M | 2.87 M | - | -1.17 M | -2.02 M | -1.68 M | - | -890 K | -2.64 M | -1.8 M | - | -657 K | -2.18 M | -1.55 M | - | -610 K | -3.51 K | -1.34 M | - |
Depreciation & Amortization |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15 K | 38.3 K | 29.4 K | - | 6.13 K | 33 K | 18.1 K | 126 K | 4.39 K | 12.4 K | 7.37 K | 81.3 K | 10.5 K | 32.1 K | 21.3 K | 81.3 K | 3.85 K | 24.9 K | 13.9 K | 81.3 K | 1.02 K | 244 K | 81.3 K | 81.3 K | 70.5 K | 233 K | 81.3 K | 81.4 K | 1.42 K | - | - | - | 2.08 K | - | - | - | 1.93 K | 5.99 K | 3.98 K | - |
Accounts Payables |
148 K | 165 K | 276 K | 284 K | - | 525 K | 302 K | 215 K | 364 K | 206 K | 94 K | 195 K | 504 K | 265 K | 227 K | 93 K | 512 K | 136 K | 208 K | 136 K | 367 K | 232 K | 232 K | 232 K | 613 K | 586 K | 586 K | 586 K | 417 K | 582 K | 582 K | 582 K | 541 K | 480 K | 480 K | 480 K | 560 K | 373 K | 373 K | 373 K | 578 K | 375 K | 375 K | 375 K | 492 K | 540 K | 540 K | 540 K | 489 K | 527 K | 527 K | 527 K | 449 K | 305 K | 305 K | 305 K | - | 375 K | 375 K | 375 K |
Accounts Receivables |
- | - | - | - | - | 173 K | 410 K | 218 K | 391 K | 270 K | 334 K | 256 K | - | 47 K | - | - | - | - | - | - | 22.3 K | 2.23 K | 5.95 K | 32.3 K | - | 66.5 K | 66.5 K | 66.5 K | - | 307 K | 307 K | - | - | - | 221 K | - | - | - | - | - | 45 K | - | - | - | - | 400 K | 400 K | 400 K | - | 175 K | 175 K | 175 K | - | 7 K | - | - | - | - | - | - |
Total Inventories |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 33.4 K | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Anixa Biosciences, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
$ 114.25 | -1.07 % | $ 34.7 B | ||
|
Biodesix
BDSX
|
$ 15.55 | 3.19 % | $ 2.02 B | ||
|
Biomerica
BMRA
|
$ 2.17 | - | $ 4.98 M | ||
|
BioNano Genomics
BNGO
|
$ 1.2 | -0.03 % | $ 6.53 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 16.5 | 1.85 % | $ 178 M | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
CareDx, Inc
CDNA
|
$ 18.32 | 0.05 % | $ 976 M | ||
|
Celcuity
CELC
|
$ 113.8 | 1.04 % | $ 5.32 B | ||
|
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
$ 4.4 | 101.83 % | $ 5.85 M | ||
|
Charles River Laboratories International
CRL
|
$ 168.44 | -3.13 % | $ 8.35 B | ||
|
Castle Biosciences
CSTL
|
$ 24.85 | 0.04 % | $ 690 M | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 197.89 | 0.37 % | $ 22 B | ||
|
Danaher Corporation
DHR
|
$ 190.62 | -0.26 % | $ 136 B | ||
|
DexCom
DXCM
|
$ 62.7 | 0.76 % | $ 24.5 B | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Fulgent Genetics
FLGT
|
$ 16.8 | -0.15 % | $ 508 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Guardant Health
GH
|
$ 92.35 | -1.58 % | $ 11.6 B | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
ICON Public Limited Company
ICLR
|
$ 110.38 | -3.34 % | $ 9.1 B | ||
|
Interpace Biosciences
IDXG
|
$ 1.96 | 5.82 % | $ 8.67 M | ||
|
Illumina
ILMN
|
$ 127.63 | 0.2 % | $ 20.3 B | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
- | - | $ 19.8 B | ||
|
IQVIA Holdings
IQV
|
$ 168.24 | -2.9 % | $ 28.9 B | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 274.94 | 0.41 % | $ 22.9 B | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
$ 76.0 | -0.14 % | $ 5.13 B | ||
|
Medpace Holdings
MEDP
|
$ 485.89 | -2.5 % | $ 14 B | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Mettler-Toledo International
MTD
|
$ 1 258.2 | -0.3 % | $ 25.9 B | ||
|
Myriad Genetics
MYGN
|
$ 4.84 | 1.79 % | $ 448 M | ||
|
ENDRA Life Sciences
NDRA
|
$ 4.69 | - | $ 3.69 M | ||
|
NeoGenomics
NEO
|
$ 8.06 | 0.75 % | $ 1.03 B | ||
|
Neogen Corporation
NEOG
|
$ 9.42 | 0.11 % | $ 2.04 B | ||
|
National Research Corporation
NRC
|
$ 17.35 | 1.11 % | $ 388 M | ||
|
Natera
NTRA
|
$ 207.01 | -0.46 % | $ 20.4 B | ||
|
Pacific Biosciences of California
PACB
|
$ 1.36 | 1.49 % | $ 408 M | ||
|
Koninklijke Philips N.V.
PHG
|
$ 27.09 | -0.07 % | $ 20 B | ||
|
Precipio
PRPO
|
$ 25.23 | -1.29 % | $ 40.5 M | ||
|
Personalis
PSNL
|
$ 6.63 | 0.76 % | $ 393 M | ||
|
RadNet
RDNT
|
$ 55.12 | 0.6 % | $ 4.14 B |